期刊
EUROPEAN JOURNAL OF IMMUNOLOGY
卷 51, 期 9, 页码 2296-2305出版社
WILEY
DOI: 10.1002/eji.202149234
关键词
SARS-CoV-2; COVID-19; N-terminal domain; NTD; serology; immunogen
类别
资金
- Pasteur International Network Association
- Bill and Melinda Gates Foundation [OPP1170236, INV-004923]
- University of Illinois at Urbana-Champaign
- US National Institutes of Health [HHSN272201400006C]
- National Natural Science Foundation of China (NSFC)/Research Grants Council (RGC) Joint Research Scheme [N_HKU737/18]
- National Research Foundation of Korea (NRF) - Korea government [NRF-2018M3A9H4055203]
- Research Grants Council of the Hong Kong Special Administrative Region, China [T11-712/19-N]
- Guangdong Province International Scientific and Technological Cooperation Projects [2020A0505100063]
- National Research Foundation of Korea [2018M3A9H4055203] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Specific antibodies against SARS-CoV-2 NTD can be induced during infection, but show less cross-reactivity with the 2003 pandemic strain SARS-CoV. When used as an immunogen, NTD rarely induces neutralizing antibodies, suggesting it may not be suitable for vaccine development.
The increasing numbers of infected cases of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses serious threats to public health and the global economy. Most SARS-CoV-2 neutralizing antibodies target the receptor binding domain (RBD) and some the N-terminal domain (NTD) of the spike protein, which is the major antigen of SARS-CoV-2. While the antibody response to RBD has been extensively characterized, the antigenicity and immunogenicity of the NTD protein are less well studied. Using 227 plasma samples from COVID-19 patients, we showed that SARS-CoV-2 NTD-specific antibodies could be induced during infection. As compared to the results of SARS-CoV-2 RBD, the serological response of SARS-CoV-2 NTD is less cross-reactive with SARS-CoV, a pandemic strain that was identified in 2003. Furthermore, neutralizing antibodies are rarely elicited in a mice model when NTD is used as an immunogen. We subsequently demonstrate that NTD has an altered antigenicity when expressed alone. Overall, our results suggest that while NTD offers a supplementary strategy for serology testing, it may not be suitable as an immunogen for vaccine development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据